Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Ibuprofen vs ACETAMINOPHEN, ASPIRIN AND CAFFEINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Dysmenorrhea,Fever reduction,Juvenile idiopathic arthritis,Patent ductus arteriosus closure (off-label),Pericarditis (off-label),Gout (off-label)
FDA-approved: Temporary relief of minor aches and pains (headache, muscle ache, toothache, backache, menstrual cramps), reduction of fever.,Off-label: None commonly accepted.
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
Acetaminophen: 2-4 hours (prolonged in liver disease); aspirin: 15-20 minutes (active metabolite salicylate: 2-3 hours at low doses, prolonged to 15-30 hours at high doses); caffeine: 3-6 hours (prolonged in pregnancy, liver disease).
Primarily hepatic via CYP2C9 (major) and CYP2C8 (minor); also undergoes glucuronidation. Metabolites are inactive.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP2E1 (toxic metabolite NAPQI); Aspirin: hydrolyzed to salicylate, further metabolized by conjugation (glycine, glucuronic acid) and oxidation; Caffeine: hepatic via CYP1A2 (major), CYP2E1, CYP3A4, N-acetyltransferase.
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Acetaminophen: renal elimination of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%, unchanged 2%); aspirin: renal elimination of salicylate and metabolites (75% salicyluric acid, 10% glucuronides, 10% salicylate); caffeine: renal elimination of metabolites (paraxanthine, theobromine, theophylline; <3% unchanged). Total: >95% renal.
99% bound primarily to albumin.
Acetaminophen: 10-25% (albumin); aspirin: 80-90% (albumin, decreased at high doses); caffeine: 35% (albumin).
0.1-0.2 L/kg; low Vd consistent with high protein binding and limited tissue distribution.
Acetaminophen: 0.9-1.0 L/kg; aspirin: 0.15-0.2 L/kg (low); caffeine: 0.6-0.8 L/kg. Reflects distribution into total body water.
Oral: 80-100% (rapidly and completely absorbed).
Acetaminophen: oral 85-98%; aspirin: oral 50-80% (due to first-pass hydrolysis); caffeine: oral ~100%.
GFR 30-60 m L/min: no adjustment needed; GFR 15-29 m L/min: 200 mg every 12 hours; GFR <15 m L/min: avoid use.
Contraindicated in severe renal impairment (Cr Cl <10 m L/min). For Cr Cl 10-50 m L/min: avoid aspirin component; consider alternative therapy. For Cr Cl >50 m L/min: no adjustment needed for acetaminophen; aspirin may require dose reduction or monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: caution with acetaminophen (max 2 g/day) and avoid caffeine if severe. Child-Pugh B: avoid aspirin; reduce acetaminophen dose (max 2 g/day) and limit caffeine. Child-Pugh C: contraindicated due to aspirin and acetaminophen risk.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day.
Not recommended for children <12 years due to aspirin risk of Reye's syndrome. For adolescents ≥12 years: same as adult dosing: 1-2 tablets every 4-6 hours, max 8 tablets/24 hours.
Start at lowest effective dose (200 mg every 8-12 hours); maximum 400 mg/day due to increased risk of GI bleeding and renal impairment.
Caution due to increased sensitivity to aspirin (GI bleeding, renal impairment) and caffeine (insomnia, tachycardia). Start at low end of dosing: 1 tablet every 6 hours; monitor renal function and avoid long-term use.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk may increase with duration of use. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
Reye syndrome warning: Aspirin should not be used in children or teenagers with viral illnesses due to risk of Reye syndrome.
Cardiovascular thrombotic events,Gastrointestinal ulceration, bleeding, perforation,Hypertension,Heart failure exacerbation,Renal toxicity (including acute renal failure, interstitial nephritis),Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic effects (e.g., anemia, prolonged bleeding time),Hepatic impairment,Asthmatic reactions in aspirin-sensitive patients
Hepatotoxicity (acetaminophen overdose), gastrointestinal bleeding (aspirin), Reye syndrome (aspirin in children with viral illness), cardiovascular risk (aspirin may increase bleeding), caffeine-related CNS stimulation, risk of dependence.
Hypersensitivity to ibuprofen or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in coronary artery bypass graft surgery,Active gastrointestinal bleeding, ulceration, or perforation,Advanced renal disease,Pregnancy (third trimester),Severe heart failure (NYHA class IV),Cerebrovascular bleeding
Hypersensitivity to any component; active peptic ulcer disease; bleeding disorders; severe hepatic impairment; children/adolescents with viral illness (Reye syndrome); third trimester of pregnancy (aspirin); concurrent use of other salicylates or NSAIDs; severe renal impairment.
Alcohol: increases GI irritation and bleeding risk. Grapefruit juice: no significant interaction. High-fat meals may delay absorption but do not reduce overall bioavailability.
Alcohol increases risk of hepatotoxicity with acetaminophen and GI bleeding with aspirin. Caffeine-containing foods or beverages should be limited to avoid excessive caffeine intake. High-tyramine foods (e.g., aged cheeses, cured meats) may potentiate caffeine effects; no significant interaction documented.
First trimester: NSAID use associated with increased risk of miscarriage and congenital anomalies (e.g., cardiac defects, gastroschisis). Second trimester: Avoid due to potential oligohydramnios and fetal renal impairment. Third trimester: Contraindicated; risk of premature ductus arteriosus closure, persistent pulmonary hypertension, oligohydramnios, and fetal nephrotoxicity.
First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible association with gastroschisis. Second trimester: Aspirin may increase risk of intracranial hemorrhage; acetaminophen and caffeine generally not linked to major malformations. Third trimester: Aspirin use is contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios; high-dose acetaminophen may cause oligohydramnios; caffeine metabolism slows, but moderate intake appears safe; chronic high-dose caffeine may be associated with low birth weight.
Ibuprofen is compatible with breastfeeding. M/P ratio approximately 0.6–1.1. Transfer into breast milk is low; relative infant dose <1% maternal weight-adjusted dose. Preferred NSAID during lactation due to short half-life and low infant exposure.
Acetaminophen: M/P ratio approximately 0.9; small amounts excreted; considered safe. Aspirin: M/P ratio variable, typically 0.12-0.42; avoid high doses due to risk of Reye's syndrome; single doses unlikely harmful. Caffeine: M/P ratio approximately 0.5-1.0; moderate intake (≤300 mg/day) considered safe; excessive intake may cause irritability in infant.
Physiological changes in pregnancy (increased volume of distribution, renal clearance) may reduce serum concentrations. However, no specific dose adjustment is routinely recommended. Use lowest effective dose for shortest duration. Avoid in third trimester.
Acetaminophen: No dose adjustment needed; standard dosing (650-1000 mg every 4-6 hours, max 3000 mg/day). Aspirin: Avoid doses >81 mg/day in third trimester; use lowest effective dose. Caffeine: Metabolism prolonged; limit to ≤200 mg/day (approximately 2 cups coffee).
Ibuprofen has a ceiling effect for analgesia; exceeding 400 mg per dose provides minimal additional pain relief but increases GI and cardiovascular risks. Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min) or active peptic ulcer disease. In asthma patients, note that NSAIDs can trigger bronchospasm in approximately 10% of aspirin-sensitive individuals. For acute pain, a single dose of 400-800 mg is effective; for chronic use, use the lowest effective dose for the shortest duration. Ibuprofen is highly protein-bound and may displace warfarin, increasing INR; monitor closely.
Acetaminophen, aspirin, and caffeine combination is used for mild to moderate pain and fever reduction. Aspirin component provides anti-inflammatory effects; caution in patients with bleeding disorders or those on anticoagulants due to increased bleeding risk. Acetaminophen hepatotoxicity risk with doses >4g/day or in liver disease. Caffeine may cause insomnia, tremor, or palpitations; avoid in patients with anxiety disorders. Reye syndrome risk with aspirin use in children with viral illnesses. Monitor renal function in elderly or dehydrated patients.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day without a doctor's approval; maximum OTC dose is 400 mg every 4-6 hours.,Avoid alcohol while taking ibuprofen to reduce the risk of stomach bleeding.,Stop taking and contact your doctor if you experience signs of stomach bleeding: black or bloody stools, vomiting blood, or severe abdominal pain.,Ibuprofen can increase risk of heart attack or stroke, especially with long-term use or high doses; discuss your cardiovascular risk with your doctor.,Do not take ibuprofen if you are pregnant (especially in the third trimester) unless directed by your doctor, as it can harm the unborn baby.
Do not exceed recommended dose; acetaminophen overdose can cause liver damage.,Avoid alcohol while taking this medication.,Do not use in children or teenagers with viral illnesses due to Reye syndrome risk.,May cause stomach upset; take with food or milk.,Limit caffeine intake from other sources when using this medication.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Triamterene, a potassium-sparing diuretic, can inhibit the hepatic metabolism of caffeine by competing for cytochrome P450 (CYP) 1A2, the primary enzyme responsible for caffeine clearance. This leads to increased plasma caffeine concentrations and prolonged caffeine half-life, potentially causing caffeine toxicity manifesting as nervousness, insomnia, tachycardia, and diuresis enhancement. Patients may experience exaggerated stimulant effects and increased risk of cardiac arrhythmias when combining these agents."
"Caffeine inhibits the metabolism of sulfadiazine by competitively antagonizing cytochrome P450 (CYP) enzymes, particularly CYP1A2, leading to increased plasma concentrations of sulfadiazine. This elevates the risk of dose-dependent adverse effects, including crystalluria, nephrotoxicity, and hypersensitivity reactions. The interaction may also reduce the therapeutic efficacy of sulfadiazine due to altered pharmacokinetics."
"Caffeine inhibits the cytochrome P450 enzyme CYP2C9, which is primarily responsible for the metabolism of losartan to its active metabolite E-3174. This inhibition can lead to increased plasma concentrations of losartan and decreased formation of the active metabolite, potentially reducing losartan's antihypertensive efficacy. The clinical outcome may be suboptimal blood pressure control in patients consuming high amounts of caffeine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Ibuprofen vs ACETAMINOPHEN, ASPIRIN AND CAFFEINE, answered by our medical review team.
Ibuprofen is a NSAID that works by Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is a NSAID / Antiplatelet that works by Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Ibuprofen and ACETAMINOPHEN, ASPIRIN AND CAFFEINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Ibuprofen is: 200-800 mg orally every 6-8 hours; maximum 3200 mg/day.. The standard adult dose of ACETAMINOPHEN, ASPIRIN AND CAFFEINE is: 1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Ibuprofen and ACETAMINOPHEN, ASPIRIN AND CAFFEINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Ibuprofen is classified as Category D/X. First trimester: NSAID use associated with increased risk of miscarriage and congenital anomalies (e.g., cardiac defects, gastroschisis). Second trimester: Avoid due to potential o. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is classified as Category D/X. First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.